M Edward1, J A Quinn, S M Pasonen-Seppänen, B A McCann, R H Tammi. 1. Section of Dermatology, Division of Cancer Sciences and Molecular Pathology, Faculty of Medicine, The Robertson Building, University of Glasgow, Glasgow G12 8QQ, UK. m.edward@clinmed.gla.ac.uk
Abstract
BACKGROUND: There is a close correlation between tumour progression and hyaluronan production, either by tumour cells or by stromal cells that are stimulated by tumour-derived factors. Inhibition of tumour stimulation of fibroblast hyaluronan may suppress tumour growth and invasion. OBJECTIVES: To examine the effect of the hyaluronan synthesis inhibitor 4-methylumbelliferone (4-MU) on the growth of and hyaluronan synthesis by fibroblasts and C8161 and MV3 melanoma cell lines, invasion, and inhibition of tumour cell-derived factor activation of fibroblasts. METHODS: Effects of 4-MU on growth and hyaluronan synthesis by fibroblasts and melanoma cells were examined in monolayer culture and fibroblast-contracted collagen lattices, and their effects on the growth and invasion of tumour cells into collagen lattices were also studied. RESULTS: 4-MU caused a dose-dependent growth inhibition of fibroblast and melanoma cells with maximum inhibition at 0·5 mmol L(-1) 4-MU. At this dose, 4-MU inhibited (3) H-glucosamine incorporation into fibroblast glycosaminoglycans by 52%, and hyaluronan synthesis by 64%. The relative inhibition was more pronounced when fibroblasts were stimulated with C8161 melanoma cell-conditioned medium. 4-MU reduced the level of hyaluronan in fibroblast-contracted collagen lattices, and inhibited both the growth on and invasion into the lattices by melanoma cells. This growth inhibition appears to be predominantly independent of inhibition of hyaluronan synthesis. The effect on growth inhibition was reversible, and 4-MU had no effect on apoptosis. CONCLUSIONS: 4-MU is a potent inhibitor of hyaluronan synthesis, induction of stromal hyaluronan accumulation by tumour cells, and fibroblast and melanoma cell proliferation, and results suggest that 4-MU may have potential as a tumour cell anti-invasive and antiproliferative agent.
BACKGROUND: There is a close correlation between tumour progression and hyaluronan production, either by tumour cells or by stromal cells that are stimulated by tumour-derived factors. Inhibition of tumour stimulation of fibroblast hyaluronan may suppress tumour growth and invasion. OBJECTIVES: To examine the effect of the hyaluronan synthesis inhibitor 4-methylumbelliferone (4-MU) on the growth of and hyaluronan synthesis by fibroblasts and C8161 and MV3 melanoma cell lines, invasion, and inhibition of tumour cell-derived factor activation of fibroblasts. METHODS: Effects of 4-MU on growth and hyaluronan synthesis by fibroblasts and melanoma cells were examined in monolayer culture and fibroblast-contracted collagen lattices, and their effects on the growth and invasion of tumour cells into collagen lattices were also studied. RESULTS:4-MU caused a dose-dependent growth inhibition of fibroblast and melanoma cells with maximum inhibition at 0·5 mmol L(-1) 4-MU. At this dose, 4-MU inhibited (3) H-glucosamine incorporation into fibroblast glycosaminoglycans by 52%, and hyaluronan synthesis by 64%. The relative inhibition was more pronounced when fibroblasts were stimulated with C8161 melanoma cell-conditioned medium. 4-MU reduced the level of hyaluronan in fibroblast-contracted collagen lattices, and inhibited both the growth on and invasion into the lattices by melanoma cells. This growth inhibition appears to be predominantly independent of inhibition of hyaluronan synthesis. The effect on growth inhibition was reversible, and 4-MU had no effect on apoptosis. CONCLUSIONS:4-MU is a potent inhibitor of hyaluronan synthesis, induction of stromal hyaluronan accumulation by tumour cells, and fibroblast and melanoma cell proliferation, and results suggest that 4-MU may have potential as a tumour cell anti-invasive and antiproliferative agent.
Authors: Brian P Teng; Melissa D Heffler; Eric C Lai; Ya-Li Zhao; Charles M LeVea; Vita M Golubovskaya; Kelli M Bullarddunn Journal: Anticancer Agents Med Chem Date: 2011-09 Impact factor: 2.505
Authors: Sunny Guin; Yuanbin Ru; Neeraj Agarwal; Carolyn R Lew; Charles Owens; Giacomo P Comi; Dan Theodorescu Journal: Clin Cancer Res Date: 2015-10-21 Impact factor: 12.531
Authors: Paul Timpson; Ewan J McGhee; Zahra Erami; Max Nobis; Jean A Quinn; Mike Edward; Kurt I Anderson Journal: J Vis Exp Date: 2011-10-13 Impact factor: 1.355
Authors: Hanna Siiskonen; Mari Poukka; Kristiina Tyynelä-Korhonen; Reijo Sironen; Sanna Pasonen-Seppänen Journal: BMC Cancer Date: 2013-04-05 Impact factor: 4.430